### Editorials

- **Measuring the Efficacy and Effectiveness of Rheumatoid Arthritis Therapy: Time to Change Our Thinking and Adopt a New Model**
  - F. Wolfe, L. Caplan, K. Michaud
  - Page 2317
- **COPCORD — An Unrecognized Fountainhead of Community Rheumatology in Developing Countries**
  - A. Chopra
  - Page 2320
- **Chronic Back Pain: Searching for Causes and Cures**
  - J.H. Atkinson
  - Page 2323
- **Matrix Catabolism in Arthritis: Priming the Guns with Oncostatin M**
  - C.D. Richards
  - Page 2326
- **Classification Criteria for Antiphospholipid Syndrome: The Case for Cardiac Valvular Disease**
  - M.A. Petri
  - Page 2329
- **High Dose Immunotherapy with Stem Cell Rescue in Severe SSc: An Idea That Is Moving Forward**
  - D.E. Furst, R. Nash, K.M. Sullivan, R. Saccardi, P. McSweeney
  - Page 2331

### Articles

- **A Distinct Multicytokine Profile Is Associated with Anti-Cyclical Citrullinated Peptide Antibodies in Patients with Early Untreated Inflammatory Arthritis**
  - C.A. Hitchon, P. Alex, L.B. Erdile, et al
  - Page 2336
- **Enhanced Fcγ Receptor I, αβ Integrin Receptor Expression by Monocytes and Neutrophils in RA: Interaction with Platelets**
  - A. Bunescu, P. Seideman, R. Lenkei, K. Levin, N. Egberg
  - Page 2347
- **Clinical Outcomes of Patients with RA After Switching from Infliximab to Etanercept**
  - Page 2356
- **Low Dose MTX in the First Trimester of Pregnancy: Result of a French Collaborative Study**
  - B. Lewden, T. Vial, E. Elefant, A. Nelva, P. Carlier, J. Descotes
  - Page 2360
- **Therapeutic Strategies in RA Over a 40-Year Period**
  - H.M. Kremers, P. Nicola, C.S. Crowson, W.M. O’Fallon, S.E. Gabriel
  - Page 2366

- **Folate, Homocysteine, and Cobalamin Status in Patients with RA Treated with MTX, and the Effect of Low Dose Folic Acid Supplement**
  - N. Hornung, T. Ellingsen, K. Stengaard-Pedersen, J.H. Poulsen
  - Page 2374
- **Autoantibodies That Stabilize U1snRNP Are a Significant Component of Human Autoantibodies to snRNP and Delay Proteolysis of Sm Antigens in Vitro**
  - Page 2382
- **Defining Response in SLE: A Study by the SLICC Group**
  - S.J. Wollaston, V.T. Farewell, D.A. Isenberg, et al
  - Page 2390
- **Systemic Sclerosis and Occupational Risk Factors: Role of Solvents and Cleaning Products**
  - A. Maitre, M. Hours, V. Bonneferre, et al
  - Page 2395
- **Primary Antiphospholipid Syndrome: A 5-Year Transesophageal Echocardiographic Followup Study**
  - N.E. Zavaleta, R.M. Montes, M.E. Soto, N.A. Vanzzini, M-C. Amigo
  - Page 2402
- **Low Level Laser Therapy in Primary Raynaud’s Phenomenon — Results of a Placebo Controlled, Double Blind Intervention Study**
  - M. Hirschl, R. Katzenschlager, C. Francesconi, M. Kundi
  - Page 2408
- **Epistatic Interactions Between HLA-DRB1 and IL-4, But Not IFN-γ, Increase Susceptibility to Giant Cell Arteritis**
  - Page 2413
- **Prolactin and Growth Hormone Responses to Hypoglycemia in Patients with RA and AS**
  - J. Rovensky, R. Imrich, F. Malis, et al
  - Page 2418
- **Clinimetric Evaluation of the BASMI in a Controlled Trial of Pamidronate Therapy**
  - Page 2422
- **Colchicine for Prophylaxis of Acute Flares When Initiating Allopurinol for Chronic Gouty Arthritis**
  - G.C. Borstad, L.R. Bryant, M.P. Abel, D.A. Scroggie, M.D. Harris, J.A. Alloway
  - Page 2429
- **Impact of OA on Quality of Life in a Hong Kong Chinese Population**
  - J. Woo, E. Lau, P. Lee, et al
  - Page 2433
- **Low Prevalence of Knee and Back Pain in Southeast China; the Shantou COPCORD Study**
  - Page 2439